Fingolimod News and Research

RSS

FDA approves new drug to treat MS in pediatric patients

The U.S. Food and Drug Administration today approved Gilenya (fingolimod) to treat relapsing multiple sclerosis (MS) in children and adolescents age 10 years and older. This is the first FDA approval of a drug to treat MS in pediatric patients.

14 May 2018

Novartis PARADIGMS study shows safety and efficacy of new treatment in pediatric MS patients

Novartis today announced full results from the positive Phase III PARADIGMS study, investigating the safety and efficacy of Gilenya (fingolimod) vs. interferon beta-1a, in children and adolescents (ages 10 to 17) with multiple sclerosis (MS).

30 Oct 2017

Established therapeutic drugs may be effective against childhood dementia

Although dementia is most often seen in adults, childhood or adolescent dementia does occur. A team of researchers from the University of Würzburg believes that established therapeutic drugs might be effective against childhood dementia.

24 Jul 2017

New treatment may hold promise for progressive form of multiple sclerosis, study suggests

A research team led by scientists from Brigham and Women's Hospital has revealed how an FDA-approved drug works in the central nervous system in mice to suppress chronic inflammation.

9 Feb 2017

IUPUI scientists develop new synthetic method to shorten drug discovery and development process

Synthesizing useful new compounds is what pharmaceutical discovery and development is all about. Researchers at the School of Science at Indiana University-Purdue University Indianapolis have devised a method to substantially speed up the process.

1 Dec 2016

S1P1R variation may cause differential patient responses to fingolimod treatment

Multiple sclerosis (MS) is an autoimmune disorder that results in demyelination of neurons. The FDA-approved drug fingolimod (Gilenya, FTY-720) modulates signaling by the bioactive lipid sphingosine-1-phosphate (S1P), which is linked to MS pathogenesis.

16 Jun 2016

PET imaging can help identify autoimmune inflammation in MS

The triggers of autoimmune inflammation in multiple sclerosis (MS) have eluded scientists for many years, but molecular imaging is bringing researchers closer to identifying them, while providing a means of evaluating next-generation therapies for MS, say researchers introducing a study at the 2016 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging.

14 Jun 2016

Real risk of rebound syndrome following fingolimod cessation for MS

Rebound syndrome following cessation of fingolimod for multiple sclerosis occurs at a clinically relevant rate, shows research, prompting the need for further study on how best to sequence and discontinue such drugs.

4 May 2016

Rituximab outperforms fingolimod after natalizumab switch

Rituximab is more effective and better tolerated than fingolimod for patients with multiple sclerosis needing to switch from natalizumab due to JC-virus antibody positivity, research suggests.

26 Apr 2016

Rituximab drug more effective than fingolimod for patients with highly active multiple sclerosis

A new study indicates that rituximab is more effective than fingolimod for preventing relapses in patients with highly active multiple sclerosis switching from treatment with natalizumab.

22 Apr 2016

Added benefit of multiple sclerosis drug fingolimod not proven, says IQWiG

Since its approval in 2011, the multiple sclerosis drug fingolimod (Gilenya) has already undergone three early benefit assessments, all of which were mainly based on the approval study TRANSFORMS. After a new modification of the therapeutic indication by the regulatory authorities, the Federal Joint Committee again commissioned the German Institute for Quality and Efficiency in Health Care to examine the added benefit of the drug in accordance with the Act on the Reform of the Market for Medicinal Products.

9 Mar 2016

Promising phase II results for ozanimod in MS

The selective sphingosine 1-phosphate receptor inhibitor ozanimod significantly reduces lesion activity in patients with relapsing-remitting multiple sclerosis, shows a phase II study published in The Lancet Neurology.

17 Feb 2016

Natalizumab shows relapse prevention benefits over fingolimod in MS

Natalizumab may be superior to fingolimod for preventing relapses during the first year of treatment in patients with relapsing–remitting multiple sclerosis, observational study findings show.

4 Feb 2016

Fingolimod trial INFORMS primary progressive MS strategy

Fingolimod is unable to slow disability progression or brain volume loss in patients with primary progressive multiple sclerosis, show the findings of the INFORMS study.

29 Jan 2016

Shorter washout period during transition from natalizumab supported

A prematurely halted trial provides support for a relatively short washout period when transitioning patients with relapsing–remitting multiple sclerosis from natalizumab to fingolimod.

5 Jun 2015

Novartis launches ‘24 Life Hacks in 24 hours’ showing commitment to help people with MS access guidance and advice

World MS Day was created by the Multiple Sclerosis International Foundation (MSIF) in 2009 to raise global awareness of MS...

28 May 2015

Study offers new insight into benefits of vitamin D in people with multiple sclerosis

In mice with a rodent form of multiple sclerosis (MS), vitamin D appears to block damage-causing immune cells from migrating to the central nervous system, offering a potential explanation for why the so-called "sunshine vitamin" may prevent or ease symptoms of the neurodegenerative disease, according to results of a study at Johns Hopkins.

9 Dec 2013

TSRI scientists identify set of compounds to treat multiple sclerosis in new way

Scientists at The Scripps Research Institute (TSRI) have identified a set of compounds that may be used to treat multiple sclerosis (MS) in a new way. Unlike existing MS therapies that suppress the immune system, the compounds boost a population of progenitor cells that can in turn repair MS-damaged nerve fibers.

10 Oct 2013

Multiple sclerosis patients see "rapid expansion" of effective new treatment options

After decades of research, multiple sclerosis patients are seeing a "rapid expansion" of effective new treatment options, according to a review article in the journal Neurologic Clinics.

14 Aug 2013

Fingolimod could potentially eliminate or reduce progression of colitis-associated cancer

After uncovering a mechanism that promotes chronic intestinal inflammation and the development of colorectal cancer, scientists from Virginia Commonwealth University Massey Cancer Center have found that fingolimod, a drug currently approved for the treatment of multiple sclerosis, could potentially eliminate or reduce the progression of colitis-associated cancer (CAC).

10 Jan 2013